NASDAQ:IMNPImmune Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume12.29 million shsMarket Capitalization$8.14 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Immune Pharmaceuticals. Previous Next 2.5 Community Rank Outperform VotesImmune Pharmaceuticals has received 255 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmune Pharmaceuticals has received 248 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmune Pharmaceuticals has received 50.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote “Outperform” if you believe IMNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMNP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmune Pharmaceuticals does not currently pay a dividend.Dividend GrowthImmune Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immune Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.85% of the stock of Immune Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.43% of the stock of Immune Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMNP Previous SymbolOTCMKTS:EPCT CUSIPN/A CIK1208261 Webwww.immunepharmaceuticals.com Phone201-464-2677Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares49,313,000Market Cap$8.14 million Next Earnings DateN/A OptionableNot Optionable Receive IMNP News and Ratings via Email Sign-up to receive the latest news and ratings for IMNP and its competitors with MarketBeat's FREE daily newsletter. Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions How were Immune Pharmaceuticals' earnings last quarter? Immune Pharmaceuticals Inc (NASDAQ:IMNP) announced its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.05. View Immune Pharmaceuticals' earnings history. Has Immune Pharmaceuticals been receiving favorable news coverage? Press coverage about IMNP stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immune Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news about Immune Pharmaceuticals. Who are some of Immune Pharmaceuticals' key competitors? Some companies that are related to Immune Pharmaceuticals include Millendo Therapeutics (MLND), Newron Pharmaceuticals (NWPHF), Akari Therapeutics (AKTX), Neos Therapeutics (NEOS), Ceapro (CRPOF), CNS Pharmaceuticals (CNSP), Tonix Pharmaceuticals (TNXP), Sunesis Pharmaceuticals (SNSS), SONNET BioTherapeutics (SONN), Alimera Sciences (ALIM), Neurotrope (NTRP), Vistagen Therapeutics (VTGN), PLx Pharma (PLXP), Spring Bank Pharmaceuticals (SBPH) and Cyclerion Therapeutics (FBRX). View all competitors. What other stocks do shareholders of Immune Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), CytRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Novavax (NVAX), DryShips (DRYS), Heat Biologics (HTBX) and Molecular Templates (MTEM). Who are Immune Pharmaceuticals' key executives? Immune Pharmaceuticals' management team includes the following people: Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)Mr. Christine J. Petraglia, Director of Investor RelationsMs. Anna Baran-Djokovic J.D., Director of Corp. AffairsDr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc What is Immune Pharmaceuticals' stock symbol? Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP." How big of a company is Immune Pharmaceuticals? Immune Pharmaceuticals has a market capitalization of $0.00. What is Immune Pharmaceuticals' official website? The official website for Immune Pharmaceuticals is www.immunepharmaceuticals.com. How can I contact Immune Pharmaceuticals? Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
